---
schema_version: "secwatch.filing_event.v1"
accession: "0000882095-25-000009"
form_type: "8-K"
ticker: "GILD"
cik: "0000882095"
company_name: "GILEAD SCIENCES, INC."
filed_at: "2025-04-24T23:59:59+00:00"
generated_at: "2026-05-23T07:44:56.800097+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Gilead Q1 revenue flat at $6.7B; GAAP EPS $1.04 vs -$3.34; cuts GAAP EPS guidance

## Summary
- Total revenue $6.7B unchanged YoY; product sales ex-Veklury up 4% to $6.3B.
- GAAP diluted EPS $1.04 vs $(3.34) in Q1 2024; non-GAAP diluted EPS $1.81 vs $(1.32).
- Biktarvy sales $3.1B (+7% YoY); HIV product sales up 6% to $4.6B.
- Full-year GAAP diluted EPS guidance cut to $5.65-$6.05 from $5.95-$6.35; product sales unchanged.
- Cash $7.9B; operating cash flow $1.8B; $1.0B dividends, $730M buyback in Q1.

## SEC filing metadata
- accession: 0000882095-25-000009
- form_type: 8-K
- ticker: GILD
- cik: 0000882095
- company_name: GILEAD SCIENCES, INC.
- filed_at: 2025-04-24T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882095/000088209525000009/0000882095-25-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882095/000088209525000009/gild-20250424.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000882095-25-000009
- JSON: https://secwatch.observer/filing/0000882095-25-000009.json
- Plain text: https://secwatch.observer/filing/0000882095-25-000009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.